BOSTON, Nov. 17, 2010 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years. The studies, which were conducted in-house by its early phase units worldwide, enrolled more than 3,000 patients. Early phase studies conducted in targeted patient populations are designed to demonstrate early signals of safety and efficacy in investigational medicines.
"To avoid costly late stage development failures, the biopharmaceutical industry has placed increased emphasis on conducting more complex, sophisticated, and rigorous early phase research, including earlier patient studies, to better predict safety and efficacy as well as identify and select the most promising new compounds. To assist clients in achieving these goals, PAREXEL provides access to numerous patient populations for early phase studies, including Proof-of-Concept studies," said Sy Pretorius, M.D., M.S., M.B.A., Corporate Vice President and Worldwide Head of Early Phase, PAREXEL. "Reaching the milestone of successfully completing the 200th early phase patient study performed in-house by our units over the last three years demonstrates our leading ability to help biopharmaceutical companies generate better and faster go/no-go decisions about their compounds."
Over several years, PAREXEL's early phase experts have developed extensive global databases of patients for inclusion in Phase I patient and Proof-of-Concept studies. The databases, which include more than 70 diverse patient populations, are complemented by the capabilities of dedicated call centers, recruitment specialists, and access to local healthcare professionals through PAREXEL's hospital-based units. PAREXEL's early phase units are strategically located to facilitate rapid patient recruitment.
As biopharmaceutical companies strive to manage development costs, gather dose range data sooner, accelerate development timelines, and obtain earlier efficacy signals, PAREXEL helps meet these multiple goals in early stage development. PAREXEL's early phase services provide fully integrated solutions from First in Man through Proof-of-Concept and help biopharmaceutical companies seeking to return solid, reproducible outcomes to succeed in later-phase trials.
PAREXEL's early phase units are located across three continents, including in Baltimore and Los Angeles in the United States; London, United Kingdom; Berlin, Germany; and Bloemfontein, George, and Port Elizabeth, South Africa. PAREXEL's early phase capabilities include a full scope of early phase studies, specialized trial design, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the oncology, neurology, cardiology, respiratory, and metabolism/endocrine therapeutic areas. For more information about PAREXEL's early phase capabilities visit: http://www.PAREXEL.com/Early_Phase.html.
About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations
Kim Baker/Gene CarozzaPAREXEL International
PAN CommunicationsTel: +781-434-4409
Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved